Fusion Antibodies (LON:FAB) Stock Price Down 2% – Here’s What Happened

Fusion Antibodies plc (LON:FAB) shares traded down 2% during mid-day trading on Tuesday . The company traded as low as GBX 9.80 ($0.12) and last traded at GBX 10 ($0.12). 3,455,756 shares traded hands during trading, a decline of 22% from the average session volume of 4,450,999 shares. The stock had previously closed at GBX 10.20 ($0.13).

Fusion Antibodies Stock Up 11.5 %

The company has a debt-to-equity ratio of 2.40, a current ratio of 3.87 and a quick ratio of 2.36. The business has a 50 day simple moving average of GBX 5.71 and a 200 day simple moving average of GBX 4.29. The stock has a market cap of £8.77 million, a PE ratio of -230.00 and a beta of 0.49.

Insider Activity at Fusion Antibodies

In other Fusion Antibodies news, insider Adrian Kinkaid acquired 83,728 shares of Fusion Antibodies stock in a transaction that occurred on Wednesday, October 16th. The stock was acquired at an average price of GBX 4 ($0.05) per share, with a total value of £3,349.12 ($4,139.83). 11.39% of the stock is currently owned by company insiders.

About Fusion Antibodies

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.